CD19 and neoplasm: Currently, the clinical trials reported so far on CAR-T cells directed towards the CD19 antigen, widely expressed by acute lymphoblastic leukemia cells (ALL), has documented a strong tumor activity (13, 14) even in patients highly resistant to conventional treatments or relapsed after allogeneic transplantation, obtaining CR rates of approximately 80%.